Spectral Gains Clarity Following FDA Meeting On PMA For Sepsis Therapy

Spectral Medical provided an update on its 100-day meeting with the U.S. FDA concerning Toraymyxin, its late-stage therapy for sepsis. The available article text does not disclose specific FDA feedback, clinical data, approval timing, or financial implications, limiting the immediate valuation impact.